Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

Abstract

Prophylactic lamivudine appears to prevent hepatitis B virus reactivation and its associated mortality in patients treated with chemotherapy. This should be confirmed with prospective studies.